Tamam Habib, MD
Hematology & Oncology · West Reading, PANPI 1295875060
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $737 of the $902 with a category attached, or 81.7%. It is spread thinly across 18 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $365 and has fallen 66.1% since, to $124 in 2025. That places this record below the midpoint for hematology & oncology clinicians in PA, where the typical reported total is $1,277.
Across 36 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$160
- Pharmacosmos Therapeutics Inc.$124
- E.r. Squibb & Sons, L.L.C.$83
- Novartis$79
- Bristol Myers Squibb$61
- Gilead$56
- plus $339 from 12 others
Across 3 payments — averaging $42,657 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$128K
What the payments were for
- Food & beverage$73782%
- Education$16518%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 5 | $160 |
| Pharmacosmos Therapeutics Inc. | 1 | $124 |
| E.r. Squibb & Sons, L.L.C. | 5 | $83 |
| Novartis | 3 | $79 |
| Bristol Myers Squibb | 3 | $61 |
| Gilead(2 entities) | 3 | $56 |
| Merck | 3 | $53 |
| Bayer | 2 | $48 |
| Foundation Medicine, Inc. | 1 | $41 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Lilly USA, LLC | 1 | $26 |
| Rigel Pharmaceuticals, Inc. | 1 | $25 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Beigene USA, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $18 |
| Array Biopharma Inc | 1 | $17 |
| CTI Biopharma Corp. | 1 | $17 |
| ADC Therapeutics America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monoferric$124
How this compares
$902 in reported general payments places this provider in the 40th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 60 | $1,443,785 |
| BrukinsaZanubrutinib | 47 | $665,965 |
| Lenalidomide | 39 | $642,262 |
| IbrancePalbociclib | 36 | $580,101 |
| ImbruvicaIbrutinib | 30 | $459,312 |
| XtandiEnzalutamide | 27 | $384,213 |
| RevlimidLenalidomide | 18 | $310,043 |
| Abiraterone Acetate | 140 | $277,369 |
| PomalystPomalidomide | 11 | $253,744 |
| InlytaAxitinib | 15 | $253,356 |
| TagrissoOsimertinib Mesylate | 15 | $224,432 |
| EliquisApixaban | 152 | $89,547 |
| XareltoRivaroxaban | 42 | $26,429 |
| Anastrozole | 357 | $6,923 |
| Deferasirox | 29 | $5,924 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $21 | $665,96547 claims |
| Bristol Myers SquibbRevlimid | $61 | $310,04318 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $83 | $253,74411 claims |
| Johnson & JohnsonXarelto | $160 | $26,42942 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in West Reading
- Andrew RettewWest Reading$164K
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.